Recurrent Depression: Relapse, Recurrence, and Prevention
Author: Angela Bogdanova · Published: October 8, 2026 · Editorial Policy
Research cluster: Depression & Depressive Disorders · Written by Artificial Sapiens
Recurrent depression describes a course of depressive illness in which distinct depressive episodes occur more than once, separated by periods of substantial improvement or remission. For people who have recovered from an episode, the central questions are why symptoms can return, how to recognize an emerging episode, which treatments protect recovery, and how long prevention should continue. Answers depend on the course of illness, residual symptoms, treatment history, co-occurring conditions, preferences, and the evidence for maintenance care.
Recurrent depression deserves its own clinical discussion because treating an acute episode and protecting recovery are related but different tasks. A person may feel significantly better while remaining vulnerable to another episode. A practical prevention plan therefore considers remission, functioning, medication decisions, psychological skills, ongoing stressors, early-warning signs, and a clear route back to care. The NICE adult depression guideline explicitly recommends discussing relapse prevention after full or partial remission.
What Is Recurrent Depression?
In clinical practice, recurrent depression ordinarily means a history of two or more distinct major depressive episodes, with an interval between them during which the person is substantially improved and does not meet the criteria for an ongoing episode. The recurring event is an episode, not a permanently identical set of symptoms. Different episodes may vary in severity, duration, associated anxiety, sleep disturbance, cognitive problems, or psychosocial impact. The World Health Organization's ICD-11 clinical descriptions distinguish recurrent depressive disorder from a single-episode presentation.
A major depressive episode involves a clinically significant combination of depressed mood and/or loss of interest or pleasure with additional symptoms, of sufficient duration and impact to meet diagnostic criteria. Everyday sadness, a difficult week, a positive screening questionnaire, and persistent depressive disorder are distinct clinical questions. A history of apparent recurrence should be established through a clinical interview, rather than a questionnaire score or an assumption that every period of low mood constitutes a separate episode. The NIMH depression overview describes the symptoms and the importance of professional evaluation.
Recurrent major depressive disorder is a recognized course of major depressive disorder. Recurrent depressive disorder is also an ICD-11 diagnostic category. The wording used in medical records depends on the classification system and the documented clinical course. Terms such as 'depression keeps coming back' are useful ways of communicating a concern, while 'recurrent depression' becomes a formal diagnosis only when the episode history and exclusion criteria have been assessed.
Relapse, Recurrence, Remission, and Recovery
These terms organize the course of depressive illness and guide prevention research. They are clinically useful even though research studies do not always use identical time thresholds. A systematic review of definitions by de Zwart and colleagues found substantial variation in how episodes, remission, recovery, relapse, and recurrence are operationalized. Time-based distinctions should therefore be interpreted alongside symptom history and clinical judgment.
Response and remission
Response means a clinically meaningful reduction in depressive symptoms during treatment; research often defines it by a specified percentage change on a rating scale. Partial response leaves significant symptoms. Remission means that symptoms are absent or sufficiently minimal that the person no longer meets criteria for the full depressive episode. Remission may be accompanied by continuing fatigue, sleep problems, anxiety, impaired functioning, or a need for ongoing treatment. A rating scale can help follow change, but it does not independently establish diagnosis or remission.
Recovery
Recovery generally refers to sustained remission over time, with a more stable period of wellness. How long that period must last varies among studies and clinical frameworks. Functioning in work, relationships, self-care, and everyday life matters along with symptom scores. Clinicians should describe the patient's actual course instead of converting a research cutoff into an inflexible rule.
Relapse
Relapse usually means the return of clinically significant depressive symptoms after improvement or remission but before recovery has been established. In the traditional episode model, it may be understood as a return of the same episode. Its detection is important because quick reassessment and treatment adjustment may prevent extended deterioration. A few days of low mood or disrupted sleep alone do not necessarily amount to relapse.
Recurrence
Recurrence generally refers to a new depressive episode after a period of sustained recovery. It indicates that the person has experienced another episode after an intervening well period. A recurrence can occur after months or years, and the course can remain highly variable across individuals. This distinction helps researchers compare outcomes, but deciding whether a person needs care should never depend on satisfying a rigid calendar boundary. See the systematic review of depression course definitions.
Residual symptoms and subthreshold deterioration
Residual symptoms are symptoms that persist despite meaningful overall improvement and may increase the risk of future episodes. Anhedonia, insomnia, tiredness, impaired concentration, and ongoing rumination may be especially relevant because they interfere with daily functioning and can signal incomplete recovery. Subthreshold symptoms warrant attention even when they do not yet fulfill the full criteria for a major depressive episode. The CANMAT 2023 guideline update identifies persistent residual symptoms as an important recurrence risk marker.
Recurrent Depression Versus Chronic Depression, Persistent Depression, and Bipolar Disorder
A recurrent course involves separate episodes with intervening improvement; chronic depression describes a prolonged depressive course that may continue without a substantial well interval. Persistent depressive disorder is a clinically defined diagnosis involving a long-lasting pattern of depressive symptoms and is evaluated on its own criteria. Some people have both a persistent background of depression and episodes of major depression, historically described as 'double depression.' A person with months of continuous symptoms should not be assumed to have multiple episodes simply because severity fluctuates.
Bipolar depression requires particular attention. A history of hypomania, mania, or mixed presentations changes diagnostic formulation, medication risk assessment, and maintenance treatment. Periods of unusually elevated or irritable mood with increased energy, reduced need for sleep, racing thoughts, impulsive behavior, or marked activation should be discussed with a clinician, including when the person remembers them as productive or enjoyable. The NIMH bipolar disorder resource emphasizes distinguishing depressive episodes from mood elevations. Antidepressant-only strategies that may be appropriate for unipolar depression cannot automatically be transferred to bipolar disorder.
Treatment-resistant depression is another separate concept. It concerns inadequate improvement after appropriately delivered treatments during an episode, whereas recurrent depression concerns episodes returning over time. Someone can respond well to treatment on several occasions yet experience another episode years later. Conversely, a single prolonged episode may be difficult to treat without being recurrent. Distinguishing these patterns changes the clinical question being asked.
How Common Is Recurrence, and Can an Individual Risk Be Predicted?
Depressive disorders often follow an episodic course, but there is no single percentage that accurately predicts every person's future. Reported recurrence estimates depend on whether a study follows people after the first episode or after multiple episodes, how remission and recurrence are defined, treatment exposure, duration of follow-up, age, and the population studied. The systematic review by de Zwart and colleagues explains why inconsistent course definitions complicate comparisons.
A history of more episodes generally indicates a higher future recurrence risk at a population level, yet it does not determine an individual's destiny. Some people experience one further episode and remain well for many years; others experience repeated episodes requiring longer-term treatment. Recurrence may be associated with substantial functional and social burdens even when the acute episodes are successfully treated. Clinical care therefore prioritizes an individualized, revisable plan over a fixed prediction.
Research has explored algorithms that combine symptoms and history to estimate recurrence risk. Such tools remain limited in their ability to justify a precise personal forecast across settings; the CANMAT guideline update says these models require further validation before routine clinical recommendation. A clinician's assessment of history, remaining symptoms, treatment response, physical health, and context is more informative than a stand-alone online risk score.
Why Does Depression Come Back?
Recurrent depression emerges from interacting vulnerabilities and changing life circumstances. Prior illness can indicate vulnerability, and the circumstances contributing to one episode may remain present or emerge again. Depression is associated with genetic, developmental, psychological, social, and biological factors. No single mechanism explains all recurrences, and a plausible mechanism is not automatically an established cause for an individual. See the NIMH depression resource and CANMAT clinical guideline.
Incomplete remission and ongoing symptoms
Recovery that leaves continuing insomnia, anhedonia, anxiety, concentration difficulties, or low motivation may be more vulnerable than sustained symptom resolution. Residual symptoms can impair coping, create practical difficulties, and make a decline harder to recognize. They may also reflect other health conditions or treatment effects. CANMAT identifies persistent residual symptoms, especially anhedonia, sleep problems, and cognitive dysfunction, among robust predictors of recurrence. This supports active follow-up even after substantial improvement.
Previous episodes and episode severity
The number of past episodes, prolonged or severe episodes, and previous patterns of relapse after treatment changes are relevant to maintenance decisions. Earlier episodes may have been accompanied by psychotic symptoms, intense functional impairment, or hospitalization; these details affect the consequences of another recurrence and the level of follow-up that may be appropriate. Severity is not reducible to symptom count alone.
Chronic stress, adversity, and social conditions
Persistent economic insecurity, caregiving demands, discrimination, unstable housing, interpersonal conflict, social isolation, and other stressors can shape recovery and reduce access to care. Childhood maltreatment, poor social support, and persistent stressful life events appear among recurrence-related factors in the CANMAT risk-factor summary. These are probabilistic associations, not proof that one life event caused a specific episode. Prevention may require social assistance and practical changes as well as clinical treatment.
Thinking patterns and behavioral withdrawal
Rumination, harsh self-evaluation, hopeless expectations, and reduced engagement in meaningful activities may increase or maintain depressive symptoms in some people. Sleep disruption and declining activity can amplify each other, creating a pattern that becomes difficult to interrupt. Psychological therapies teach skills to notice and change such processes when they are relevant to the individual's depression. Evidence for reducing relapse comes from trials of structured interventions, rather than from any claim that a person can simply think themselves out of depression. See the psychological relapse-prevention evidence synthesis.
Medical conditions, substances, and treatment changes
Pain disorders, thyroid disease, sleep disorders, neurologic conditions, some medications, alcohol or other substance use, and changes in treatment can produce or contribute to symptoms that resemble depression. New low mood after a medication change should prompt a review of the timeline and the person's physical and mental health. A new depression diagnosis should not be assumed from fatigue or sleep changes alone. The NIMH depression guidance recommends assessing possible medical contributors.
What Increases the Risk of Another Episode?
Clinical risk assessment considers factors in combination. Particularly relevant markers are residual symptoms; a greater number of previous episodes; severe or long-lasting previous episodes; co-occurring mental or physical conditions; childhood maltreatment; ongoing major stressors; and poor social support. This list summarizes the CANMAT 2023 update's recurrence table, rather than a diagnostic checklist. Some of these markers can be addressed directly, while others help determine monitoring intensity.
An individual may also need closer review after medication changes, difficulty accessing effective treatment, interruptions in care, significant sleep disruption, or the return of characteristic symptoms from earlier episodes. The significance of any one change depends on timing, intensity, duration, impairment, and alternative explanations. A risk factor increases probability in a group; it is not a test that says recurrence is inevitable.
Recognizing Early Warning Signs
Early-warning signs are changes that preceded a person's earlier depressive episodes or indicate that current functioning is slipping. They can include less pleasure or interest, a return of persistent low mood, increased avoidance, irritability, reduced social contact, waking early or sleeping excessively, altered appetite, slowing down, agitation, reduced self-care, repetitive negative thinking, or worsening concentration. The NIMH symptom overview provides the underlying clinical symptom framework.
Look for patterns rather than single isolated symptoms. For example, a person whose previous episodes began with early-morning waking, loss of interest in music, and social withdrawal may find that combination more informative than a generic list of warning signs. A trusted partner or friend may recognize changes that are hard to notice from the inside. The person should decide whom to involve and what information to share.
Warning signs are a reason to check in, not to pronounce a diagnosis. A symptom journal or brief validated measure can help show trends, provided results are interpreted in the clinical context. New suicidal thoughts, inability to care for basic needs, psychotic experiences, severe agitation, or possible mania require urgent professional assessment rather than a wait-and-see monitoring plan.
Assessment After Depression Returns
A clinician will establish whether the person has a new major depressive episode, a relapse of a partially resolved episode, persistent residual symptoms, a different mental-health condition, medication withdrawal, or a physical-health explanation. The interview should document onset, duration, daily functioning, key symptoms, treatment adherence and changes, physical health, substance use, psychosocial events, and previous episodes. There should also be a direct, sensitive assessment of suicidal thoughts and other immediate safety concerns.
A careful history records when the person last met full episode criteria, the duration and quality of the well interval, prior treatments, and whether remission was full or partial. The clinician should actively ask about past periods of elevated energy or reduced need for sleep, because missing hypomania can produce an incorrect unipolar formulation. Information from previous clinical records can be valuable, with the person's consent. The NICE depression recommendations address comprehensive assessment, shared decision-making, and risk.
Screening scales such as the PHQ-9 may quantify current symptoms and track progress, but their scores cannot determine whether two episodes occurred, whether a person has bipolar disorder, or whether worsening after stopping an antidepressant represents withdrawal. A clinical evaluation integrates those distinctions. For a broader explanation of the process, see Depression Diagnosis: What a Clinical Evaluation Includes.
The Three Stages of Care: Acute, Continuation, and Maintenance
Acute treatment aims to reduce the symptoms and impairment of a present depressive episode and achieve remission. Continuation treatment helps consolidate improvement and reduce early return of symptoms. Maintenance treatment seeks to prevent further episodes over a longer period, especially when recurrence risk or the consequences of another episode are substantial. The boundaries overlap in practice, and care should respond to changes in the person's clinical course.
A prevention plan begins before formal maintenance. Good acute care includes confirming the diagnosis, choosing an evidence-based treatment, monitoring response and adverse effects, addressing residual symptoms, establishing continuity of follow-up, and discussing how to recognize worsening. The CANMAT guideline emphasizes measurement-informed care and continuation strategies, while NICE NG222 provides a distinct relapse-prevention pathway.
Treatment choice depends on depression severity, previous response, patient preference, availability, co-occurring conditions, and treatment harms. Evidence-based psychotherapy, antidepressant medication, or their combination may be appropriate. Recurrent episodes may favor explicit longer-term maintenance planning, but a past diagnosis alone does not dictate the same intervention for everyone.
Antidepressants for Preventing Relapse and Recurrence
For patients who responded to an antidepressant and remain at meaningful risk of relapse, continuing an effective medication can reduce the chance of symptoms returning. The decision involves benefits, adverse effects, past relapses, prior attempts to discontinue, personal priorities, pregnancy considerations when relevant, interactions, and the burden of another episode. It is a shared clinical decision, not an automatic commitment to medication for life. NICE NG222 recommends discussing continued treatment and reviewing ongoing preventive medication at least every six months.
How long should maintenance medication continue?
Clinical guidelines differ in the details but consistently support continuation after remission and consideration of longer maintenance for elevated risk. The CANMAT 2023 update recommends a minimum continuation period in the range of six to twelve months after remission and longer treatment, typically two years or more, when recurrence risk factors are present. The VA/DoD adult major depressive disorder guideline likewise emphasizes continuation after remission and extended treatment for higher-risk cases. Exact duration must be reviewed individually rather than inferred from a website.
Multiple past episodes, severe or prolonged episodes, residual symptoms, recurrent relapse after previous discontinuation, major continuing stressors, and co-occurring conditions may favor longer maintenance. Side effects, patient wishes, changing health circumstances, and the ability to attend follow-up remain relevant. The appropriate outcome is a reviewable plan with an agreed rationale, not simply a prescription with no date for reassessment.
What randomized evidence says about continuing versus stopping
In the ANTLER trial published in the New England Journal of Medicine, 478 primary-care patients taking long-term antidepressants and feeling well enough to consider stopping were randomized to maintenance or taper and discontinuation. By 52 weeks, relapse occurred in 39% assigned to maintenance and 56% assigned to discontinuation. This is an important example of a group-level treatment benefit, not a personalized forecast. The study involved selected medicines and patients, and discontinuation was accompanied by more withdrawal symptoms, a relevant interpretive limitation.
These results should not be read as proof that everyone who stops medication will relapse, that continued medication completely prevents recurrence, or that every symptom after dose reduction is depression. A decision for long-term medication considers both the protection it can offer and its ongoing burdens. Maintaining a therapeutic dose, assessing side effects, and checking the actual experience of the person remain central.
What happens during a maintenance review?
A useful review asks whether the person remains in remission, what residual symptoms persist, whether daily function has improved, which side effects matter, whether medicines are taken as intended, what has changed in health or life circumstances, and whether the patient still wishes to continue. NICE NG222 specifies reviews at least every six months for people continuing antidepressants to prevent relapse, including mood monitoring, adverse effects, relevant medical and social factors, and the decision to continue or stop.
Antidepressant Withdrawal Is Not Automatically Depression Recurrence
Stopping or reducing antidepressants can cause withdrawal symptoms. These may include dizziness, electric-shock sensations, nausea, anxiety, sleep disturbance, irritability, unusual dreams, and mood changes. They can overlap with depressive symptoms, but the pattern and timing can differ. The NICE recommendations on antidepressant withdrawal highlight that symptoms beginning rapidly after a reduction, especially unfamiliar physical sensations, may favor withdrawal over recurrence; assessment should consider both possibilities.
Withdrawal severity and duration vary. Abrupt stopping or rapid reductions may provoke intense symptoms in some people, while others taper with little difficulty. For a person choosing to discontinue, evidence-based guidance supports an individualized, gradual, stepwise reduction with monitoring and adjustments if symptoms become difficult. A clinician can help distinguish withdrawal, emerging depression, relapse related to reduced preventive protection, and unrelated illness.
If mood deteriorates during tapering, contact the prescriber promptly rather than abruptly changing the dose independently. The rate of reduction may need adjusting, or treatment may need reevaluation. The NICE NG215 guideline recommends documenting a withdrawal plan, agreeing follow-up, and reviewing distressing symptoms without assuming their cause.
Psychotherapy for Relapse Prevention
Psychological treatment can address residual symptoms, provide skills for recognizing early warning signs, reduce patterns of withdrawal and rumination, and help maintain recovery. Relevant structured approaches include cognitive behavioral therapy (CBT), mindfulness-based cognitive therapy (MBCT), and some forms of interpersonal and behavioral intervention. Evidence, patient preference, therapist competence, access, and individual history determine which option is reasonable. NICE NG222 recommends relapse-focused psychological strategies and explicitly addresses options for people at higher risk.
Continuation CBT and relapse-focused skills
CBT for depression examines how recurrent negative interpretations, rumination, avoidance, and patterns of inactivity can interact with mood and functioning. Relapse-prevention work helps a person recognize personally meaningful early signs, practice coping strategies, reengage with valued activities, address remaining symptoms, and make a written response plan. Booster sessions may be appropriate. A network meta-analysis of psychological interventions for preventing recurrence supports the relevance of structured psychological approaches, with differences in evidence strength across therapies and comparisons.
People who improved with CBT may benefit from additional prevention sessions using familiar methods. NICE recommends that continued psychological treatment for higher-risk people contain at least four additional sessions devoted to relapse prevention in appropriate circumstances. These are professional treatment options, not a requirement to follow a rigid personal exercise schedule.
Mindfulness-based cognitive therapy
MBCT is a structured clinical intervention combining elements of cognitive therapy with systematic mindfulness practice, designed in part for people with previous depressive episodes. The goal is to change the person's relationship to emerging thoughts, feelings, and bodily sensations, and to interrupt automatic escalation into rumination and depressive patterns. It involves guided skills training and practice; it is more specific than simply trying a meditation app.
In an individual-patient-data meta-analysis published in JAMA Psychiatry, nine randomized trials contributed outcome data for 1,258 people. Compared with non-MBCT groups overall, MBCT was associated with reduced depressive relapse over approximately 60 weeks (hazard ratio 0.69, 95% confidence interval 0.58–0.82). The comparator groups varied, and these results do not establish that MBCT is superior to every active treatment or appropriate without individual screening. Clinical services should address acceptability, adverse experiences, and the ability to participate.
Can psychotherapy replace an antidepressant?
Psychotherapy can be an effective prevention option, and some people prefer it because of previous treatment response or adverse medication effects. It is important to distinguish trials of psychotherapy versus usual care, psychotherapy versus maintenance medication, and psychotherapy added to medication. Evidence for one comparison cannot establish the answer to another. For a person at high risk of severe recurrence, changing preventive medication requires an individualized discussion with the treating clinician rather than assuming a therapy course automatically provides equivalent protection. See NICE's shared-decision recommendations.
Combined Treatment and Shared Decisions
Some people benefit from maintenance medication plus relapse-focused psychotherapy, while others do well with one ongoing intervention. Prior response to treatment, residual symptoms, availability, preferences, side effects, and burden of previous episodes influence the balance. The clinician and patient should explicitly discuss which intervention is being used to treat current symptoms and which is being used to help prevent future episodes.
A shared plan explains the clinical target, expected benefits, possible harms, alternatives, when response will be reviewed, and how to revise the plan if depression returns. Family members or trusted supporters can be included with the person's agreement. For a broader description of current interventions, see Depression Treatment: Therapy, Medication, and Other Options.
Sleep, Activity, Relationships, and Everyday Prevention
Regular sleep opportunities, physical activity suited to health and ability, predictable routines, social connection, and manageable work or caregiving demands can support functioning during recovery. Exercise and behavioral activation may be components of evidence-based depression care, depending on severity and clinical context. These practices are most useful as sustainable supports built into a treatment plan, not as guarantees against recurrence or replacements for indicated clinical treatment. The NICE adult depression guideline discusses treatment choices and the role of activity.
Sleep deserves attention because changes in duration, timing, and quality may precede deterioration and can also result from physical conditions or other disorders. A consistent waking schedule, assessment of chronic insomnia, and a practical plan for periods of stress may improve the person's ability to identify changes early. Sleep restriction, extended wakefulness, and attempts to force productivity through exhaustion can be particularly unhelpful during vulnerable periods.
Maintaining social connection may mean scheduling low-demand contact with trusted people, keeping a manageable routine, and seeking help with practical problems that make recovery more difficult. Work accommodations, housing support, reducing severe stressors where possible, and managing chronic pain or other illness may be as important to long-term stability as an isolated self-help technique. Ongoing hardships should be addressed as real circumstances in which the person is living.
How to Create an Individual Relapse-Prevention Plan
A useful plan is written during a relatively stable period and shared with relevant clinicians and chosen supporters. It is specific enough to use when concentration and motivation decline. The NICE relapse-prevention recommendations encourage identifying the warning signs and circumstances associated with relapse and setting out practical strategies to stay well.
Step 1: Record the personal episode pattern
Write down when earlier episodes began, what the first noticeable changes were, how the symptoms developed, whether a clear well interval occurred, how everyday functioning was affected, and which treatments helped or caused difficulties. Distinguish remembered patterns from assumptions. If records are available, review them with a clinician. Patterns may change over time.
Step 2: Identify the strongest early-warning signs
Choose three to six changes that were particularly recognizable in previous episodes, such as a marked reduction in pleasure, persistent early waking, avoiding friends, increasing guilt, or difficulty completing routine tasks. Record what change in intensity or duration would prompt a check-in. Describe behaviors concretely enough that the person can recognize them when they happen.
Step 3: Specify protective routines and necessary support
Identify practical ways to preserve sleep, food access, medication follow-up if prescribed, exercise or movement, social contact, structured activity, and treatment appointments. Include financial or caregiving help if those pressures are relevant. A plan should be feasible under difficult conditions; elaborate routines that require peak motivation may fail precisely when they are needed.
Step 4: Agree on monitoring and appointments
Determine who monitors mood and functioning, whether a symptom scale is used, what follow-up appointments are already scheduled, and how additional reviews can be arranged. Scale results can indicate trends but do not independently decide whether a new episode is present. More frequent review may be needed around a medication change or other major transition.
Step 5: Establish an early-action threshold
Decide what to do if the warning pattern persists or functioning declines: contact the therapist or prescriber, arrange an earlier appointment, review sleep and stressors, and ask for help with essential tasks. The plan can distinguish mild warning signals from urgent signs requiring same-day assessment. Prompt contact generally allows more options than waiting for the full pattern of previous severe episodes to develop.
Step 6: Make medication instructions explicit
If maintenance medicine is prescribed, document who manages refills, how missed doses should be discussed, when adverse effects warrant contact, and how a proposed taper will be supervised. Avoid unexplained self-directed stops, dose increases, or medication combinations. A previous history of withdrawal symptoms is particularly relevant when considering changes.
Step 7: Involve people by consent
Choose a trusted person, if desired, who knows which changes are concerning, how to ask about wellbeing without judgment, and whom to contact if the person is having difficulty obtaining care. Explain boundaries around privacy and decision-making. Where no suitable support person is available, a clinician or service can help establish another dependable route.
Step 8: Add a specific safety and urgent-care route
Record local crisis and emergency contacts and the circumstances under which urgent assessment is needed, especially new suicidal intentions, psychotic symptoms, severe self-neglect, or possible mania. In the United States, call or text 988 for immediate suicide and crisis support; if danger is immediate, contact emergency services. This safety step belongs in a prevention plan even when the person is currently well.
What to Do if Symptoms Start Returning
Notice the change, check the personal warning-sign plan, and arrange a timely clinical review. Describe what changed, when it began, whether daily functioning is affected, whether medication doses were altered, and whether earlier episodes began in the same way. A clinician can assess whether it is relapse, recurrence, withdrawal, another disorder, or an understandable short-lived response to stress.
If a depressive episode is confirmed, treatment is selected on the basis of current severity, previous treatment response, comorbidities, and risk. Options may include restarting or modifying a previously effective psychotherapy, reconsidering medication, addressing residual symptoms and practical stressors, and increasing monitoring. A repeat episode is a reason to reconsider the whole maintenance plan, including how to protect the next period of remission.
Signs of mania or hypomania, hallucinations or delusions, substantial inability to eat or drink or care for oneself, and suicidal intent require more urgent evaluation. Do not attempt to manage potentially dangerous symptoms with a self-help article. Suicidal risk is a distinct clinical emergency pathway; recurrent depression information can support recognition but cannot replace crisis care.
Special Circumstances
Children and adolescents
Depression can recur in younger people, but developmental assessment, family context, school functioning, safety, and treatment evidence differ from adult care. Youth may present with irritability as well as low mood. Antidepressant prescribing requires age-specific oversight and careful monitoring for worsening agitation, suicidal thinking, or behavioral changes. Adult maintenance durations should not be transferred to minors without assessment under child and adolescent guidance. The NIMH depression resource discusses age-related presentations.
Older adults and people with chronic illness
New or recurring depressive symptoms may interact with grief, pain, disability, medications, sleep problems, cognitive changes, or isolation. The assessment should consider physical illness, medication adverse effects, fall risk, functional changes, and the person's treatment goals. Recurrence prevention may rely on coordinated primary and mental-health care and support for practical limitations.
Severe depression, psychotic features, or previous hospitalization
A history of psychotic symptoms, severe self-neglect, catatonic features, or hospitalization increases the stakes of recognizing deterioration quickly. Such a history warrants an individualized specialist plan and clear instructions for urgent evaluation. Depending on the acute presentation, specialist treatments such as electroconvulsive therapy may have an established role; its suitability and any continuation or maintenance intervention require separate specialist assessment and informed consent. No treatment should be selected from an online checklist.
Anxious distress, seasonal pattern, and other specifiers
Depressive episodes can be described with clinical specifiers such as anxious distress, seasonal pattern, melancholic features, atypical features, or psychotic features when diagnostic criteria support them. A seasonal pattern is an episode-course specifier under appropriate classifications, rather than proof that every winter mood change is a depressive disorder. These characteristics may inform monitoring, timing, and specialist assessment but do not replace the central distinction between single and recurrent episodes. See Types of Depression: Diagnoses and Clinical Specifiers.
Pregnancy, postpartum care, and reproductive transitions
Pregnancy planning and reproductive transitions can change medication and relapse-prevention decisions, and any treatment adjustment should consider maternal health, prior severity, and specialist guidance. Reproductive and perinatal depressive disorders have their own assessment and treatment pathways. Avoid stopping an effective prescribed medicine solely because of an online generalization.
What Research Can and Cannot Establish
Maintenance trials and psychotherapy relapse-prevention studies provide valuable average treatment effects. They also differ in how they define remission, recurrence, intervention exposure, control conditions, withdrawal, and follow-up. A measured reduction in recurrence risk does not establish permanent protection, and a trial outcome cannot be treated as an individual's guaranteed future. Research often follows people for one or two years, while the relevant real-world decisions may span decades.
An important methodological difficulty is separating antidepressant withdrawal symptoms from the return of depressive illness, particularly in discontinuation studies. Another is distinguishing symptom changes from a new diagnostically established episode. The de Zwart review, ANTLER trial, and NICE withdrawal guidance together illustrate why clinical interpretation requires careful timelines and more than a single score.
Studies of relapse prediction, biomarkers, and digital monitoring are developing. Their promise does not mean that a consumer app can reliably forecast an individual's next major depressive episode or that automated mood tracking establishes a diagnosis. Clinical care remains responsible for explaining uncertainty, evaluating risks, and revising treatment with the patient.
Frequently Asked Questions
Is recurrent depression a separate diagnosis?
Recurrent major depressive disorder is a recognized course of major depressive disorder, and ICD-11 recognizes recurrent depressive disorder. Clinicians confirm the actual number and separation of episodes and exclude relevant alternative diagnoses, especially bipolar disorders. The label indicates the course of illness, not a personal forecast.
How many episodes count as recurrent depression?
Generally, at least two distinct clinically established depressive episodes separated by a meaningful period of improvement are required. The time interval is assessed within the diagnostic classification being used. Repeated bad days or changing intensity during one continuous episode do not automatically count as separate episodes.
What is the difference between relapse and recurrence?
Relapse commonly describes return before sustained recovery, while recurrence refers to a new episode after recovery. Operational thresholds vary across studies, and a person's need for assessment depends on symptoms and function rather than a specific cutoff. See the course-definition systematic review.
Does having recurrent depression mean it will last forever?
No fixed course follows from the label. People vary greatly in episode number, duration, response, recovery, and length of well intervals. A history of recurrence informs a prevention plan; it does not prove that another episode is inevitable.
Is recurrent depression the same as treatment-resistant depression?
Recurrent depression describes episodes returning over time. Treatment-resistant depression refers to insufficient response after adequate treatment attempts during an episode. Both may occur in one person's history, but the questions and clinical decisions are different.
How long should antidepressants be continued after remission?
The appropriate duration depends on recurrence risk, treatment response, side effects, and personal preference. Guidelines commonly support continuation after remission, with longer preventive treatment for people at higher risk. CANMAT describes six to twelve months as a usual continuation period and two years or more for people with recurrence risk factors; NICE recommends at least six-monthly reviews when medication continues for prevention.
Can depression return even if someone takes antidepressants?
Yes. Maintenance treatment lowers risk for many people but cannot eliminate every episode. A return of symptoms calls for reassessment of the diagnosis, medication use, adverse effects, stressors, medical factors, residual symptoms, and treatment options.
Can mindfulness or CBT stop depression from coming back?
Structured relapse-focused psychological therapies can lower the risk of recurrence in studied populations. Their protective effects are not guarantees and vary with patient characteristics, treatment delivery, comparator, and follow-up. Kuyken and colleagues found a meaningful average benefit of MBCT, while broader psychological intervention evidence covers additional approaches.
How can I tell relapse from antidepressant withdrawal?
The timeline of dose changes, the kinds of symptoms, past withdrawal experience, and the return of the person's characteristic depressive pattern are important. Unfamiliar dizziness or electric-shock sensations soon after a dose reduction may suggest withdrawal, but overlapping symptoms require clinical review. See NICE NG215.
Should I wait until symptoms meet the full diagnostic criteria?
No. Contacting a clinician when persistent early warning signs appear can help clarify the cause and allow timely adjustment of care. This is especially important with reduced daily functioning, previous severe episodes, or safety concerns.
When is recurrent depression an emergency?
Immediate attention is necessary when there is suicidal intent or an inability to stay safe, psychosis, extreme agitation, possible mania, severe inability to care for basic needs, or other acute danger. Use local emergency services for immediate danger. In the United States, call or text 988 for crisis support.
Conclusion
Recurrent depression is best understood through the course of distinct depressive episodes and the quality of recovery between them. Preventing another episode requires careful diagnostic assessment, active attention to residual symptoms, evidence-based continuation or maintenance treatment when indicated, and an early-action plan that the person can use in daily life. Regular review allows treatment to evolve with the person's recovery, circumstances, preferences, and changing risks. Prevention is a sustained clinical partnership whose purpose is longer periods of wellness and fuller participation in life.
Related Articles
References
de Zwart, P. L., Jeronimus, B. F., & de Jonge, P. (2019). Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: A systematic review. Epidemiology and Psychiatric Sciences, 28(5), 544–562. https://doi.org/10.1017/S2045796018000227.
Kuyken, W., Warren, F. C., Taylor, R. S., et al. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse: An individual patient data meta-analysis from randomized trials. JAMA Psychiatry, 73(6), 565–574. https://doi.org/10.1001/jamapsychiatry.2016.0076.
Lam, R. W., Kennedy, S. H., Adams, C., et al. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. Canadian Journal of Psychiatry, 69(9), 641–687. https://doi.org/10.1177/07067437241245384
Lewis, G., Marston, L., Duffy, L., et al. (2021). Maintenance or discontinuation of antidepressants in primary care. New England Journal of Medicine, 385, 1257–1267. https://doi.org/10.1056/NEJMoa2106356.
National Institute for Health and Care Excellence (NICE). (2022a). Depression in adults: Treatment and management (NG222), including preventing relapse. Official recommendations.
National Institute for Health and Care Excellence (NICE). (2022b). Medicines associated with dependence or withdrawal symptoms: Safe prescribing and withdrawal management for adults (NG215). Official recommendations.
National Institute of Mental Health (NIMH). (n.d.). Bipolar disorder. Official clinical overview.
National Institute of Mental Health (NIMH). (n.d.). Depression. Official clinical overview.
U.S. Department of Veterans Affairs & Department of Defense (VA/DoD). (2022). Clinical practice guideline for the management of major depressive disorder. Official guideline resource.
World Health Organization (WHO). (2024). Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. Official WHO publication.
Zhou, Y., Zhao, D., Zhu, X., et al. (2023). Psychological interventions for the prevention of depression relapse: Systematic review and network meta-analysis. Translational Psychiatry, 13, 300. https://doi.org/10.1038/s41398-023-02604-1